Skip to main content

Table 3 Treatment regimens analysed among the eligible studies

From: Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review

Treatment regimens

Treatment regimen subgroups

Containing PIB

PIB + GLE

PIB + GLE + RBV

PIB + PTV/r + RBV

Containing DCV

DCV + SOF

DCV + SOF + RBV

Containing GZR

GZR + RZR + MK-3682

GZR + EBR + MK-3682

GZR/EBR + SOF

Containing Peg-IFN

Peg-IFN + RBV

Peg-IFN + SOF + RBV

Containing LDV

LDV + SOF

LDV + SOF + RBV

Containing OBV

OBV + PTV/r

OBV + PTV/r + RBV

OBV + PTV/r + SOF

OBV + PTV/r + SOF + RBV

Containing SOF

SOF + RBV

Containing VEL

VEL100 + SOF

VEL100 + SOF + VOX

VEL100 + SOF + RBV

  1. DCV daclatasvir, EBR elbasvir, GLE glecaprevir, GZR grazoprevir, LDV ledipasvir, OBV ombitasvir, Peg-IFN pegylated interferon, PIB pibrentasvir, PTV paritaprevir, RBV ribavirin, r ritonavir, SOF sofosbuvir, RZR ruzasvir, VEL100 velpatasvir 100 mg, VOX voxilaprevir